Orforglipron

Yes — the first FDA-approved GLP-1 medicine that is a small molecule rather than a peptide, backed by two real Phase 3 trials and now approved in two countries. Its genuine claim to fame isn't being the first oral GLP-1 drug (semaglutide's Rybelsus got there in 2019) — it's being the first one that doesn't require the fasting and water restrictions that oral peptide absorption still needs.

What it is

Orforglipron is a synthetic, orally-bioavailable small molecule that activates the GLP-1 receptor — the same receptor semaglutide, tirzepatide and liraglutide act on — without being a peptide itself. It was discovered by Chugai Pharmaceutical Co. of Japan under the internal code OWL833, then licensed worldwide to Eli Lilly on 26 September 2018 (Lilly's internal designation LY3502970) for a $50 million upfront payment, up to $140 million in regulatory-milestone payments and up to $250 million in sales-milestone payments, plus tiered royalties from the mid-single digits to low teens on any future sales. A pharmacology paper comparing orforglipron directly against danuglipron — Pfizer's competing, ultimately discontinued small-molecule oral GLP-1 candidate, covered on its own page on this site — found orforglipron binds the human GLP-1 receptor with high affinity (Ki = 1 nM) at a different site than the native peptide hormone or peptide-based drugs use, favoring G-protein/cAMP signaling with little of the beta-arrestin recruitment that peptide agonists produce (Sloop et al., Sci Transl Med 2024;16(778):eadp5765, DOI 10.1126/scitranslmed.adp5765, PMID 39693407). Because it isn't a peptide, orforglipron is chemically stable in stomach acid and isn't broken down by the digestive enzymes that make peptide hormones like native GLP-1 impossible to swallow as a plain pill — the same underlying reason oral semaglutide (Rybelsus) instead needs a specific absorption-enhancing formulation, discussed below.

What the trial evidence shows

Two separate placebo-controlled Phase 3 trials, both published in the New England Journal of Medicine, back the two indications orforglipron is being pursued for. ATTAIN-1 (Wharton et al., N Engl J Med, published online 16 September 2025, DOI 10.1056/NEJMoa2511774) randomized 3,127 adults with obesity or overweight, without diabetes, to once-daily orforglipron at 6mg, 12mg or 36mg, or placebo, for 72 weeks. Mean weight loss was 7.5% (6mg), 8.4% (12mg) and 11.2% (36mg), versus 2.1% on placebo; on the highest dose, 59.6% of participants lost at least 10% of body weight and 39.6% lost at least 15%, versus a small fraction on placebo. ACHIEVE-1 (Rosenstock et al., N Engl J Med, published online 21 June 2025, DOI 10.1056/NEJMoa2505669, PMID 40544435) tested the same drug in 559 adults with early type 2 diabetes (baseline HbA1c 8.0%) over 40 weeks at 3mg, 12mg and 36mg doses: HbA1c fell by 1.24, 1.47 and 1.48 percentage points respectively, versus 0.41 points on placebo.

FDA approval and dosing

The FDA approved orforglipron on 1 April 2026 under NDA 220934, as Foundayo, for chronic weight management in adults with obesity, or overweight with at least one weight-related medical condition, alongside a reduced-calorie diet and increased physical activity — the same population definition used for Wegovy and Zepbound. The approved dosing titrates upward roughly monthly: 0.8mg once daily to start, increasing after at least 30 days to 2.5mg, then after at least another 30 days to 5.5mg, with further optional increases (also spaced at least 30 days apart) up to a maximum of 17.2mg once daily, available in six tablet strengths (0.8, 2.5, 5.5, 9, 14.5 and 17.2mg). A separate type 2 diabetes indication had not yet been approved as of this review; Lilly has indicated it intended to pursue that filing separately in 2026.

The approval itself came with a genuinely notable process story attached: it was the fifth product cleared under the FDA's Commissioner's National Priority Voucher (CNPV) pilot program — a scheme meant to compress a standard 10-12 month drug review into 1-2 months for applications matching one of five designated national priorities, using a collaborative, tumor-board-style internal review rather than the usual sequential one — and the first new molecular entity approved under that program. The FDA cleared it roughly 50 days after the application was filed, 294 days ahead of its original 20 January 2027 PDUFA target date, making it the fastest new-molecular-entity approval the agency had granted since 2002.

The UK, and everywhere else: one drug, different clocks

The UK's MHRA authorised orforglipron (also marketed as Foundayo) on 10 August 2026 — the first regulator in Europe to approve it, ahead of the EU's own EMA. Unlike the FDA's narrower initial approval, the MHRA cleared it for both indications at once: weight loss and weight maintenance in adults with a BMI of 30 or above (or 27-30 with at least one weight-related comorbidity), and separately to improve glycaemic control in adults with insufficiently controlled type 2 diabetes. That authorisation is not the same as NHS availability — a licensed medicine still needs a separate NICE technology appraisal before the NHS will fund it, and as of this review no such appraisal had concluded; the drug was expected to reach the UK market only through private prescription and pharmacist-led Patient Group Direction services in the near term. As of this review, orforglipron remained under active regulatory review with no confirmed approval date in the EU (EMA), Australia (where Eli Lilly Australia lodged a submission with the Therapeutic Goods Administration before the end of 2025, with a decision estimated in late 2026 or 2027) and Canada (under Health Canada review since at least early 2026, with no announced timeline). No brand name has been publicly confirmed for the Australian or Canadian markets as of this review.

Safety notes

Gastrointestinal side effects dominate the profile, consistent with every other GLP-1-class drug on this site. In ATTAIN-1, nausea occurred in 28.9%, 35.9% and 33.7% of the 6mg, 12mg and 36mg groups respectively, versus 10.4% on placebo; diarrhea in 21.0-23.1% versus 9.6%; constipation in 21.7-29.8% versus 9.3%; and vomiting in 13.0-24.0% versus 3.5%. Discontinuation due to adverse events rose with dose: 5.3% (6mg), 7.9% (12mg) and 10.3% (36mg), against 2.7% on placebo. Foundayo's label carries the same boxed warning for thyroid C-cell tumors that every approved GLP-1 receptor agonist carries, based on rodent studies of drugs pharmacologically active in rats and mice. Orforglipron's own labeling states it specifically is not pharmacologically active in rats or mice and did not produce tumors in the rodent studies conducted on it — but also states, just as specifically, that because orforglipron is pharmacologically active at the human GLP-1 receptor, the human relevance of the GLP-1-receptor-dependent thyroid C-cell tumors seen with other drugs in rodents "has not been determined." The boxed warning and its accompanying contraindication (a personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2) therefore apply to Foundayo as a class-wide labeling requirement, not because of a tumor finding in orforglipron's own animal data.

Not the first oral GLP-1 — the first one without the food-and-water rule

Some early coverage of Foundayo's approval described it loosely as "the first GLP-1 pill," which overstates the claim. Novo Nordisk's Rybelsus (oral semaglutide) has been FDA-approved since 2019 — but semaglutide is still a peptide, and getting a peptide through the stomach intact requires real formulation engineering: Rybelsus is co-formulated with an absorption enhancer (SNAC) and has to be taken on an empty stomach with no more than about four ounces of plain water, followed by a further 30-minute wait before eating, drinking, or taking other oral medications. Orforglipron's actual, checkable claim is narrower and real: because it isn't a peptide and doesn't depend on that absorption-enhancer mechanism, it can be taken at any time of day, with or without food or water — a genuine formulation difference from Rybelsus, not a difference in which drug came first.